VERIGENE RESPIRATORY VIRUS NUCLEIC ACID TEST +(RVNAT+)— 510(k) K103209

Clearance details

Applicant

Nanosphere, Inc.

Product code

Code OCC

Device class

Class 2

Regulation

21 CFR 866.3980

Advisory panel

Microbiology

Date received

2010-11-01

Decision date

2011-01-10

Decision

Substantially Equivalent

Clearance type

Traditional

Location

Northbrook, IL, US

• K262747 — ID NOW Influenza A & B 2; ID NOW RSV; ID NOW Strep A 2; ID NOW COVID-19 2.02026-08-31
• K254139 — BioCode® Respiratory Pathogen Panel (RPP)2026-05-01
• K242613 — NxTAG® Respiratory Pathogen Panel2024-10-02
• K232775 — ID NOW Influenza A & B 22023-10-10
• K231017 — Panther Fusion AdV/hMPV/RV Assay2023-05-05

• K143653 — Verigene Respiratory Pathogens Flex Nucleic Acid Test (RP Flex)2015-09-04
• K140083 — VERIGENE ENTERIC PATHOGEN NUCLEIC ACID TEST ( EP)2014-06-20
• K132843 — VERIGENE GRAM NEGATIVE BLOOD CULTURE NUCLEIC ACID TEST (BC-GN)2014-01-08
• K123197 — VERIGENE C. DIFFICILE NUCLEIC ACID TEST (CDF)2012-12-05
• K120466 — VERIGENE CYP2C19 NUCLEIC ACID TES (2C19)2012-11-06

Death

3

Malfunction

706

Total

709

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

• Z-2684-2014 — The Verigene Respiratory Virus Plus Nucleic Acid Test (RV+) on the Verigene System is a qualitative nucleic acid multiplex test intended to simultaneously detect and identify multiple respiratory virus nucleic acids in nasopharyngeal (NP) swab specimens from individuals with signs and symptoms of respiratory tract infection. The following virus types and subtypes are identified using the RV+: Influenza A, Influenza A subtype H1, Influenza A subtype H3, 2009 H1N1, Influenza B, Respiratory Syncytial Virus (RSV) subtype A, and RSV subtype B. The test is not intended to detect Influenza C virus. Detecting and identifying specific viral nucleic acids from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection, if used in conjunction with other clinical and laboratory findings. Negative results for Influenza A, Influenza B, or RSV do not preclude influenza virus or RSV infection and should not be used as the sole basis for diagnosis, treatment, or patient management decisions. Conversely, positive results do not rule-out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. The use of additional laboratory testing and clinical presentation must be considered in order to obtain the final diagnosis of respiratory viral infection. Performance characteristics for Influenza A Virus were established when Influenza A/H3, A/H1, and 2009 H1N1 were the predominant Influenza A viruses circulating. These characteristics may vary when other Influenza A viruses are emerging. If infection with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions used specifically for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.Class II·Terminated·Nanosphere, Inc.·20131010

Matched by K-number from FDA's Recall Enterprise System record (openFDA device/recallk_numbers) — these recalls explicitly list K103209.